This CME-certified activity focuses on the management and treatment of patients diagnosed with EGFR-mutant non-small cell lung cancer (NSCLC) and includes clinical scenarios that mimic a patient receiving multiple lines of treatment. The case includes patient history, laboratory results, and options for next steps in treatment, while expert faculty provide commentary and insight.
Suresh Ramalingam, MDWinship Cancer Institute
Atlanta, Georgia, United States
Heather Wakelee, MDStanford University
Stanford, California, United States
Rathi Pillai, MDWinship Cancer Institute
Atlanta, Georgia, United States
- EGFR-mutant NSCLC
- First-line treatment of EGFR-mutant NSCLC
- Management of adverse events in EGFR-mutant NSCLC
- Incorporation of biopsy into treatment decisions in EGFR-mutant NSCLC
- Third generation tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC
- Third generation TKI failure in EGFR-mutant NSCLC
This educational activity is specifically designed for medical oncologists, pulmonologists, pathologists, nurses, advanced practice professionals, and other healthcare professionals who manage and treat patients with lung cancer.
After successful completion of this educational activity, participants should be able to:
- Select optimal treatment for EGFR-mutant NSCLC based on patient and disease characteristics, including molecular data
- Differentiate toxicity profiles of EGFR TKIs and describe strategies for managing treatment-related adverse events in EGFR-mutant NSCLC
- Evaluate current and emerging agents and treatment strategies for EGFR-mutant NSCLC
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by a grant from Boehringer Ingelheim.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Dr Pillai has disclosed that she has received consulting fees from Natera, Inc. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Ramalingam has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, Merck, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Wakelee has disclosed that she has received consulting fees from Novartis and Peregrine. She has also performed contracted research for Bristol-Myers Squibb, Celgene, Clovis, Lilly, Medimmune, Novartis, Pfizer, Roche/Genentech, and Xcovery. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed:
- Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
- Sheila Waters, MSN (senior director clinical operations content reviewer/planner) – no relevant financial relationships
- Briana Betz, PhD (clinical content reviewer/planner) – no relevant financial relationships
- Christi Gray (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.